{"@id":"https://bioecon.ru/technology/t-cell-engagers-against-solid-tumors/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://bioecon.ru/technology/t-cell-engagers-against-solid-tumors/","json":"https://bioecon.ru/api/v1/technology/t-cell-engagers-against-solid-tumors/index.json"},"id":"t-cell-engagers-against-solid-tumors","industries":["pharma","biomanufacturing"],"lang":"ru","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/orf-genetics/","https://bioecon.ru/companies/wildtype/","https://bioecon.ru/companies/esco-aster/","https://bioecon.ru/companies/simple-planet/","https://bioecon.ru/companies/cellmeat/","https://bioecon.ru/companies/integriculture/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/shin-etsu-chemical/","https://bioecon.ru/companies/newlimit/","https://bioecon.ru/companies/cryoport-systems/"]},"maturity":7,"name":"Т-клеточные активаторы против солидных опухолей","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"Дизайн биспецифических молекул"},{"n":2,"title":"Сайленсинг Fc и продление клиренса"},{"n":3,"title":"Проникновение в строму"},{"n":4,"title":"Контроль цитокинового шторма"}],"summary":"Мультиспецифические антитела, связывающие цитотоксические Т-лимфоциты через CD3 с антигенами солидных опухолей и активирующие лизис в условиях иммуносупрессивной микросреды.","url":"/technology/t-cell-engagers-against-solid-tumors/","verified":"2026-11-22"}